The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

about

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis.Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?

P2860

Q33833623-B92BAB89-CEAB-4CDE-9F06-2DEE733B1F3B Q39042940-3EFC1839-F47E-40C4-B8EF-E6ACC69CBB27

P2860

The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q38755133

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

The safety of tumor necrosis f ...... tment of rheumatoid arthritis.

@en

type

Item

label

The safety of tumor necrosis f ...... tment of rheumatoid arthritis.

@en

prefLabel

The safety of tumor necrosis f ...... tment of rheumatoid arthritis.

@en

P1476

The safety of tumor necrosis f ...... tment of rheumatoid arthritis.

@en

P2093

Maria Victoria Hernández

http://www.w3.org/2001/XMLSchema#string

P2860

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Inflammation in atherosclerosis

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.

Ankylosing spondylitis, psoriatic arthritis, and risk of malignant lymphoma: a cohort study based on nationwide prospectively recorded data from Sweden.

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

P304

613-624

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14740338.2016.1160054

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Juan D Cañete

R Sanmarti

María Victoria Hernández

P577

2016-02-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26927029

http://www.w3.org/2001/XMLSchema#string

The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

about

P2860

P2860

The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698